New York, Jan 14, 2026, 05:46 EST — Premarket
- Before the bell, Viatris shares were indicated at about $13.37, following a 5.4% rise in the previous session.
- During his JPM Healthcare Conference appearance, CEO Scott Smith highlighted the company’s cash flow and outlined its business mix.
- Investors are watching for follow-through in the last days of the conference and any new information on 2026 priorities.
Viatris Inc shares showed little movement in premarket trading Wednesday, following a more than 5% jump the day before. The stock was indicated near $13.37.
The J.P. Morgan Healthcare Conference holds weight because it can quickly change the sector’s mood, particularly for mid-cap firms where a single comment from management can steer the conversation. For Viatris, investors are zeroed in on one question: will it keep converting its vast portfolio into cash, and how will it deploy those proceeds.
Viatris came about in November 2020 when Mylan merged with Pfizer’s Upjohn unit, creating a company with a portfolio blending generics and established brands. While that mix offers some stability, it’s still vulnerable to price fluctuations and currency shifts.
On Tuesday’s regular session, Viatris surged 5.4%, finishing at $13.37 after swinging between $12.53 and $13.40. Trading volume spiked to around 15.6 million shares, a big jump from about 6.1 million the previous day, per Yahoo Finance data.
At the conference, CEO Scott Smith described Viatris as “three separate businesses” and highlighted the company’s recent cash performance. He reported $14.1 billion in revenue for the past 12 months and free cash flow of $2.2 billion, according to a transcript of the event. Seeking Alpha
Free cash flow represents the cash remaining after covering the costs of running and maintaining the business, and it frequently influences how investors value companies lacking rapid growth. Viatris also highlighted EBITDA — a basic gauge of operating profit before interest, taxes, and other non-cash expenses — as investors look to compare cash generators within the drug industry.
The conference remarks felt more like a recap than a breaking announcement, arriving just as investors remain eager to back companies demonstrating consistent cash flow and well-defined capital return strategies.
Executives across the sector are leveraging the San Francisco event to tout cost reductions, pipeline strategies, and tighter M&A controls, while investors demand concrete details. The conference runs from Jan. 12 through Jan. 15.
That said, the rally isn’t without risks. Pricing for generic drugs can shift abruptly, and setbacks like underwhelming product launches, legal troubles, or currency swings could dent earnings in a sector known for razor-thin margins.
Investors are focused on what Viatris management will reveal in the last days of the conference, particularly around their 2026 priorities. All eyes will also be on whether Tuesday’s rally sparks additional buying ahead of Thursday’s close.
